TY - JOUR
T1 - Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction
AU - Barbash, Gabriel I.
AU - Hod, Hanoch
AU - Roth, Arie
AU - Miller, Hilton I.
AU - Rath, Shemuel
AU - Zahav, Yedahel Har
AU - Modan, Michaela
AU - Zivelin, Ariela
AU - Laniado, Shlomo
AU - Seligsohn, Uri
PY - 1989/12/1
Y1 - 1989/12/1
N2 - Increased levels of plasminogen activator inhibitor (PAI) have recently been described in patients with acute myocardial infarction (AMI). To correlate PAI levels to patency of infarct arteries after thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA), 125 consecutive patients with AMI were examined. Blood levels off fibrinogen, plasminogen, tissue plasminogen activator (t-PA) and PAI were measured before treatment initiation, 10 minutes after completion of rt-PA infusion and 24 and 48 hours after treatment. Coronary angiography, performed in all patients 72 hours after beginning rt-PA infusion, revealed patent infarct arteries in 97 patients and occluded infarct arteries in 28 patients. Pretreatment levels of PAI were significantly higher in patients with occluded infarct arteries (18.0 ± 11.5 vs 10.5 ± 9.3 IU/ml, p < 0.01). Conceivably, higher levels of PAI may interfere with the natural thrombolytic process and make pharmacologic thrombolytic intervention less effective.
AB - Increased levels of plasminogen activator inhibitor (PAI) have recently been described in patients with acute myocardial infarction (AMI). To correlate PAI levels to patency of infarct arteries after thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA), 125 consecutive patients with AMI were examined. Blood levels off fibrinogen, plasminogen, tissue plasminogen activator (t-PA) and PAI were measured before treatment initiation, 10 minutes after completion of rt-PA infusion and 24 and 48 hours after treatment. Coronary angiography, performed in all patients 72 hours after beginning rt-PA infusion, revealed patent infarct arteries in 97 patients and occluded infarct arteries in 28 patients. Pretreatment levels of PAI were significantly higher in patients with occluded infarct arteries (18.0 ± 11.5 vs 10.5 ± 9.3 IU/ml, p < 0.01). Conceivably, higher levels of PAI may interfere with the natural thrombolytic process and make pharmacologic thrombolytic intervention less effective.
UR - http://www.scopus.com/inward/record.url?scp=0024350804&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(89)90559-6
DO - 10.1016/0002-9149(89)90559-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0024350804
SN - 0002-9149
VL - 64
SP - 1231
EP - 1235
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 19
ER -